Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.

Launched by POLYCLINIQUE LYON NORD · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the involvement of a hospital pharmacist can help patients starting oral cancer treatments at home. The pharmacist's role is to provide important information about the new medication, ensure a smooth connection between the hospital and the local pharmacy, and help patients manage any side effects they may experience. The goal is to see if having this support improves how well patients follow their treatment plans and handle any unwanted effects compared to those who do not receive this extra help.

To be eligible for the trial, participants should have a cancer diagnosis (but not blood cancers) and be starting a new oral treatment that they will take at home. They should not have started treatment more than 30 days before joining the study. During the trial, participants will fill out a questionnaire to share their experiences and feedback, which will help researchers understand the benefits of having a pharmacist involved in their care. This study is not yet recruiting participants, but it aims to improve cancer care and support for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient suffering from an oncological pathology (excluding hematological malignancies)
• • Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments).
• • Patient who has not yet started treatment or who has started treatment less than 30 days
• • Patient with continuation of oral therapy dispensed in pharmacies
• Exclusion Criteria:
• • Patients suffering from hematological malignancies
• • Patient living in an institution or hospital
• • Patient under treatment for more than 30 days
• • Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment)
• • Patient whose treatment after initiation is not dispensed in a pharmacy